Montréal- and Boston-based DropGenie has added BDC Capital’s Thrive Fund to its seed-plus financing, bringing the round to US$5 million.
Led by Skeleton Key, the financing also includes Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec.
DropGenie’s technology miniaturizes gene-editing experiments onto a chip, using up to 100 times fewer cells than conventional methods, according to the company. That could help researchers work with scarce patient samples while reducing material costs.
The funding will support commercialization and data partnerships, with the company targeting demand for high-quality biological datasets that can support drug discovery and AI model development.
Want to know more? Check out the source code on BetaKit.











